Prognostic Value of Serum AFP, AFP-L3, and GP73 in Monitoring Short-term Treatment Response and Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation |
Wang, Nan-Ya
(Department of Cancer Center, First Hospital of Jilin University)
Wang, Cong (Department of Cancer Center, First Hospital of Jilin University) Li, Wei (Department of Cancer Center, First Hospital of Jilin University) Wang, Guan-Jun (Department of Cancer Center, First Hospital of Jilin University) Cui, Guo-Zhen (Department of Cancer Center, First Hospital of Jilin University) He, Hua (Department of Cancer Center, First Hospital of Jilin University) Zhao, Heng-Jun (Department of Cancer Center, First Hospital of Jilin University) |
1 | Toyoda H, Kumada T, Tada T, et al (2011). Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alphafetoprotein in hepatocellular carcinoma patients with alphafetoprotein <20 ng/mL. Cancer Sci, 102, 1025-31. DOI ScienceOn |
2 | Witjes CD, van Aalten SM, Steyerberg EW, et al (2013). Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis. Hepa Inter, 7, 59-64. DOI |
3 | Yamamoto K, Imamura H, Matsuyama Y, et al (2009). Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol, 16, 2795-2804. DOI |
4 | Yamamoto K, Imamura H, Matsuyama Y, et al (2010). AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol, 45, 1272-82. DOI |
5 | Yamashita T, Forgues M, Wang W, et al (2008). EpCAM and -fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res, 68, 1451-61. DOI ScienceOn |
6 | Yoshida S, Kurokohchi K, Arima K, et al (2002). Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol, 20, 305-9. |
7 | Sterling RK, Wright EC, Morgan TR, et al (2012). Frequency of Elevated Hepatocellular Carcinoma (HCC). Biomarkers in Patients With Advanced Hepatitis C. Am J Gastroenterol, 107, 64-74. DOI ScienceOn |
8 | Saito Y, Shimada M, Utsunomiya T, et al (2012). Prediction of recurrence of hepatocellular carcinoma after curative hepatectomy using preoperative Lens culinaris agglutininreactive fraction of alpha-fetoprotein. Hepatol Res, 42, 887-94. DOI ScienceOn |
9 | Schutte K, Bornschein J, Malfertheiner P (2009). Hepatocellular carcinoma-epidemiological trends and risk factors. Digest Dis, 27, 80-92. |
10 | Shariff MI, Cox IJ, Gomaa AI, et al (2009). Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroent, 3, 353-67. DOI ScienceOn |
11 | Taketa K, Sekiya C, Namiki M, et al (1990). Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology, 99, 508-18. DOI |
12 | Tamura Y, Suda T, Arii S, et al (2013). Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment. Dig Dis Sci, 58, 2406-12. DOI ScienceOn |
13 | Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al (2000). Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol, 31, 302-08. DOI ScienceOn |
14 | Tateishi R, Shiina S, Yoshida H, et al (2006). Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology, 44, 1518-27. DOI ScienceOn |
15 | Toyoda H, Kumada T, Kaneoka Y, et al (2008). Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol, 49, 223-32. DOI ScienceOn |
16 | Llovet JM, Di Bisceglie AM, Bruix J, et al (2008). Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst, 100, 698-711. DOI ScienceOn |
17 | Hu JS, Wu DW, Liang S, Miao XY (2010). GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol, 27, 339-45. DOI ScienceOn |
18 | Ioannou GN, Perkins JD, Carithers RL, (2008). Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology, 134, 1342-51. DOI ScienceOn |
19 | Llovet JM, Bruix J (2000). Early diagnosis and treatment of hepatocellular carcinoma. Best Pract Res Cl Ga, 14, 991-1008. DOI ScienceOn |
20 | Mao Y, Yang H, Xu H, et al (2010). Golgi protein 73 (GOLPH2). is a valuable serum marker for hepatocellular carcinoma. Gut, 59, 1687-93. DOI ScienceOn |
21 | Marrero JA, Romano PR, Nikolaeva O, et al (2005). GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol, 43, 1007-12. DOI ScienceOn |
22 | Nouso K, Kobayashi Y, Nakamura S, et al (2011). Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroen Hepatol, 26, 1195-1200. DOI ScienceOn |
23 | Oka H, Saito A, Ito K, et al (2001). Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutininreactive alpha-fetoprotein. J Gastroen Hepatol, 16, 1378-83 DOI ScienceOn |
24 | Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA-Cancer J Clin, 55, 74-108. DOI ScienceOn |
25 | Riener MO, Stenner F, Liewen H, et al (2009). Golgi phosphoprotein 2 (GOLPH2). expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology, 49, 1602-09. DOI ScienceOn |
26 | Durazo FA, Blatt LM, Corey WG,, et al (2008). Des-gammacarboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroen Hepatol, 23, 1541-8. DOI ScienceOn |
27 | Carr BI, Kanke F, Wise M, Satomura S (2007). Clinical evaluation of lens culinaris agglutinin-reactive alphafetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci, 52, 776-82. DOI ScienceOn |
28 | Chong RJ, Abdullah MS, Hossain MM, Telisinghe PU, Chong VH (2013). Rising incidence of primary liver cancer in Brunei Darussalam. Asian Pac J Cancer Prev, 14, 3473-7. DOI ScienceOn |
29 | El-Serag HB, Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-76. DOI ScienceOn |
30 | Dai X, Zhao HQ, Liu RH, et al (2012). Percutaneous radiofrequency ablation guided by contrast-enhanced ultrasound in treatment of metastatic hepatocellular carcinoma after liver transplantation. Asian Pac J Cancer Prev, 13, 3709-12. DOI ScienceOn |
31 | European Association for the Study of the L, European Organisation for R, Treatment of C (2012). EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 56, 908-43. DOI ScienceOn |
32 | Fujioka M, Nakashima Y, Nakashima O, Kojiro M (2001). Immunohistologic study on the expressions of alphafetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology, 34, 1128-34. DOI ScienceOn |
33 | Fujiyama S, Tanaka M, Maeda S, et al (2002). Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology, 62, 57-63. DOI ScienceOn |
34 | Garcia M, Ward E, Center M, et al (2007). Global cancer facts & figures 2007. Atlanta, GA: American Cancer Society |
35 | Abdelgawad IA, Mossallam GI, Radwan NH, Elzawahry HM, Elhifnawy NM (2013). Can glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients? Asian Pac J Cancer Prev, 14, 7345-9. DOI ScienceOn |
36 | Bertino G, Ardiri AM, Santonocito MM, Boemi PM (2009). Some patients with HCC haven't abnornormal desgamma- carboxy prothrombin and alpha-fetoprotein levels. Panminerva Medica, 51, 133-4. |
37 | Bosetti C, Levi F, Boffetta P, et al (2008). Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology, 48, 137-45. DOI ScienceOn |
38 | Block TM, Comunale MA, Lowman M, et al (2005). Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. PNAS, 102, 779-84. DOI ScienceOn |